Moderate to severe cancer pain
Conditions
Interventions
Ruianning Group:None
OxyContin group:None
Sponsors
Ningbo Medical Centre Lihuili Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Subjects are voluntary and have signed the informed consent form for this trial. 2. Aged >= 18 years, with no gender restriction. 3. Have experienced cancer pain within the past 24 hours, with a numerical pain rating scale score >= 4, and require opioid analgesic treatment. 4. No history of allergy to narcotic drugs. 5. ECOG performance status (ECOG-PS) score = 3 months.
Exclusion criteria
Exclusion criteria: 1.Patients diagnosed with non-cancer pain or pain of unknown etiology. 2.Patients with brain metastasis accompanied by neurological symptoms. 3.Patients with contraindications to the study drug, such as paralytic ileus, chronic obstructive pulmonary disease, or cor pulmonale. 4.Severe cognitive impairment. 5.Pregnant or lactating patients. 6.Other diseases or conditions deemed ineligible for enrollment by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The number of patients whose pain has been effectively alleviated;Adverse event incidence rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Number of patients with significant pain relief (pain score reduced by >= 50%) after 1 week of treatment;Number of daily breakthrough pain episodes and duration;Daily burst pain rescue medication dosage; | — |
Countries
China
Contacts
Public ContactLiu Kaitai
Ningbo Medical Centre Lihuili Hospital
Outcome results
None listed